youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
RVMD:NASDAQ
Revolution Medicines Inc
$188.17
arrow_downward
-1.64%(-3.14) 1D
$188.17
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RVMD...
Open
$190.71
High
$192.98
Low
$187.12
Mkt. cap
40.33B
Avg. vol.
2.01M
Volume
1.37M
52-wk high
$224.31
52-wk low
$56.66
EPS
-$8.83
Beta
1.40
Shares outstanding
214.34M
No. of employees
883
Open
$190.71
High
$192.98
Low
$187.12
Mkt. cap
40.33B
Avg. vol.
2.01M
Volume
1.37M
52-wk high
$224.31
52-wk low
$56.66
EPS
-$8.83
Beta
1.40
Shares outstanding
214.34M
No. of employees
883
News stories
From web sources and news partners
Investing.com Canada
·
20 hours ago
Form 144 Revolution Medicines For: 2 November By Investing.com
About Revolution Medicines Inc
CEO-
Employees883
Founded2014
HeadquartersRedwood City, California, United States
SectorBiotechnology
Websiterevmed.com
Analyst ratings
Based on 24 analysts giving stock ratings to RVMD in the past 3 months
Strong buy
Buy
23
Hold
1
Sell
0
12-month forecast
Based on 24 Wall Street analysts offering 12 month price targets for RVMD in the last 3 months.
Highest
Current $188.17
$320.00 (+70.06%)
Average
$257.41 (+36.80%)
Lowest
$179.00 (-4.87%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Leonid Timashev RBC Capital | Buy | Maintained | $260.00 | +38.2% | 10/27/2026 |
Alec Stranahan Bank of America Securities | Buy | Maintained | $264.00 | +40.3% | 10/26/2026 |
Michael Yee UBS | Buy | Reiterated | $265.00 | +40.8% | 10/22/2026 |
Sean Laaman Morgan Stanley | Buy | Maintained | $255.00 | +35.5% | 10/22/2026 |
Tyler Van Buren TD Cowen | Buy | Reiterated | $250.00 | +32.9% | 10/21/2026 |
Brian Cheng J.P. Morgan | Buy | Maintained | - | - | 10/21/2026 |
Gregory Renza Truist Financial | Buy | Maintained | $241.00 | +28.1% | 10/19/2026 |
Michael Schmidt Guggenheim | Buy | Maintained | $275.00 | +46.1% | 10/15/2026 |
Unknown Analyst William Blair | Buy | Initiated | $226.00 | +20.1% | 10/15/2026 |
Sharon Zackfia William Blair | Buy | Initiated | $226.00 | +20.1% | 10/15/2026 |
Ami Fadia Needham | Buy | Reiterated | $275.00 | +46.1% | 10/15/2026 |
Laura Prendergast Stifel Nicolaus | Buy | Maintained | - | - | 10/08/2026 |
Charles Zhu LifeSci Capital | Buy | Maintained | $315.00 | +67.4% | 10/05/2026 |
Leah R. Cann Brookline Capital Markets | Buy | Initiated | $318.00 | +69% | 09/28/2026 |
Jeffrey Walch Bernstein | Hold | Maintained | $179.00 | -4.9% | 09/25/2026 |
Andrea Newkirk Goldman Sachs | Buy | Initiated | $267.00 | +41.9% | 09/24/2026 |
Faisal Khurshid Jefferies | Buy | Maintained | $270.00 | +43.5% | 09/03/2026 |
Sean McCutcheon Raymond James | Buy | Maintained | $248.00 | +31.8% | 08/27/2026 |
Jay Olson Oppenheimer | Buy | Maintained | $260.00 | +38.2% | 08/27/2026 |
Cory Kasimov Evercore ISI | Buy | Maintained | $320.00 | +70.1% | 08/27/2026 |
Eva Fortea Verdejo Wells Fargo | Buy | Reiterated | $240.00 | +27.5% | 08/27/2026 |
Robert Burns H.C. Wainwright | Buy | Reiterated | $280.00 | +48.8% | 08/27/2026 |
Robert Driscoll Wedbush | Buy | Maintained | $225.00 | +19.6% | 08/27/2026 |
Kalpit Patel Wolfe Research | Buy | Maintained | $220.00 | +16.9% | 08/10/2026 |
Marc Frahm TD Cowen | Buy | Reiterated | - | - | 08/10/2026 |
Joseph Catanzaro Mizuho Securities | Buy | Reiterated | $215.00 | +14.3% | 08/05/2026 |
Kelsey Goodwin Piper Sandler | Buy | Maintained | $210.00 | +11.6% | 08/06/2026 |
Unknown Analyst Bernstein | Hold | Maintained | $151.00 | -19.8% | 06/07/2026 |
Michael Morris Guggenheim | Buy | Maintained | $175.00 | -7% | 04/22/2026 |
Jonathan Chang Leerink Partners | Buy | Reiterated | $147.00 | -21.9% | 04/13/2026 |
Asthika Goonewardene Truist Financial | Buy | Maintained | - | - | 03/09/2026 |
Next call in 41:45:20
Wed, Nov 4, 4:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$2.38
Revenue / Est. (USD)
- / 27.35M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | 262.51M | 294.94M | 343.97M | 394.92M |
Cost of revenue | 262.51M | 294.94M | 343.97M | 394.92M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 52.76M | 66.68M | 101.25M | 110.21M |
Operating expense | 52.76M | 66.68M | 101.25M | 110.21M |
Total operating expenses | 315.27M | 361.63M | 445.22M | 505.13M |
Operating income | -315.27M | -361.63M | -445.22M | -505.13M |
Other non operating income | -592.00K | -12.62M | -15.90M | -151.04M |
EBT including unusual items | -305.21M | -364.89M | -453.82M | -644.37M |
EBT excluding unusual items | -305.21M | -364.89M | -453.82M | -644.37M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -305.21M | -364.89M | -453.82M | -644.37M |
Net profit margin | - | - | - | - |
Earnings per share | -1.61 | -1.86 | -2.29 | -3.06 |
Interest and investment income | 22.08M | 21.29M | 19.51M | 35.58M |
Interest expense | -11.43M | -11.94M | -12.20M | -23.78M |
Net interest expenses | 10.66M | 9.36M | 7.31M | 11.80M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -313.24M | -359.39M | -442.88M | -502.68M |
Gain or loss from assets sale | 32.00K | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events